March 13, 2024
by Ceci Connolly and Sami Inkinen
Unless you have been living under a rock, you likely have heard the names Ozempic, Wegovy or Mounjaro. Or perhaps been humming the jingle. Rarely has a class of drugs (in this case, GLP-1s) achieved such widespread attention in popular culture and the media, which has people clamoring for them in every doctor’s office in the nation.
And for good reason. What we know is that the efficacy and safety profile of these medications is substantially better than any weight loss drug in the past, while our obesity epidemic has only ballooned. As organizations committed to sound science and holistic patient care, we are encouraged by the benefits of these new therapies for diabetes. The clinical evidence shows that GLP-1s are highly effective for controlling blood glucose levels among patients living with Type 2 diabetes and certain co-morbidities. GLP-1s may even improve heart health for high-risk patients.
Read the Full Piece in The Health Care Blog
New from ACHP:
- ACHP Recommendations for an Inferred Risk Adjustment Model
- ACHP Members Lead 2027 Star Ratings and NCQA Ratings
- ACHP Urges CMS to Align State Directed Payment Policy With Plans’ Financial Risk
- Strengthening Medicare Advantage in 2028: ACHP Recommendations to CMS
- ACHP Comments on Senate Finance Health Coverage RFI
- Sens. King, Curtis Named ACHP’s 2026 Legislative Champions
